AMAZFIT
2.2.2024 15:58:27 CET | Business Wire | Press release
Amazfit, a leading global smart wearables brand owned by Zepp Health (NYSE: ZEPP), a health technology company, has today announced its groundbreaking partnership with Kelvin Kiptum, the men's marathon world record holder and only athlete to complete a marathon in under two hours and one minute. As Amazfit’s ambassador, Kiptum will utilize the Amazfit Cheetah Pro to manage training and races, and the Amazfit Helio Ring to optimize recovery, ahead of marathon races in Rotterdam and Paris.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240201514405/en/
Amazfit ambassador Kelvin Kiptum set to break marathon world record (Graphic: Business Wire)
Zepp Health expressed enthusiasm for this dynamic partnership. Pengtao Yu, VP of Industrial Design, Brand & Consumer Marketing, stated: "We are thrilled about the collaboration between Amazfit and Kelvin Kiptum. As a health technology company, we are proud to support Kelvin's quest to break records and inspire individuals worldwide to pursue their own health and fitness goals. This partnership is a testament to our commitment to empowering people to lead healthier lives through intelligent healthcare fitness solutions."
Kelvin's recent marathon achievement in Chicago, clocking a remarkable 2:00:35, sets the stage for an extraordinary collaboration. Conquering recent marathons in Valencia and London, the 24-year-old runner aims to shatter the 2-hour mark in Rotterdam this April, and clinch gold at the 2024 Olympics in Paris.
To aid his preparation, Kelvin will wear Amazfit’s Cheetah Pro. This specialist running watch features MaxTrack™ dual-band circularly-polarized GPS antenna, with 99.5% the accuracy of a professional GPS locator, along with the innovative Zepp Coach™ - an AI solution generating tailored plans for athletes looking for optimal marathon preparation. This cutting-edge technology will support Kelvin as he hones the finer details of his training.
Kelvin Kiptum shares his excitement about the collaboration, stating, "Teaming up with Amazfit for this groundbreaking journey is truly exciting. The Amazfit Cheetah Pro has become an integral part of my training regimen. As I aim to break the 2-hour mark in Rotterdam and pursue gold at the Paris Olympics, I am confident that Amazfit will be my ultimate ally in pushing the limits of human potential. Together, we are set to redefine what's possible."
This partnership extends beyond the track, with Kiptum also utilizing recently-announced Amazfit Helio Ring to take control of his recovery, with in-depth analysis of sleep quality, mental and physical Readiness, and emotional state enabled by the smart ring's BioTracker™ and EDA sensors.
The symbiosis between Amazfit and Kelvin Kiptum is emblematic of a shared commitment to breaking limits. Just as the brand's smartwatch and smart-ring are crafted for athletes seeking to push boundaries with the support of cutting-edge technology, Kelvin Kiptum continuously exemplifies the limitless potential of human ability.
By forging strategic partnerships with elite athletes like Kelvin Kiptum, Amazfit aims to create a platform that transcends geographical boundaries, providing valuable insights into performance, training, and endurance for aspiring and professional athletes.
The Amazfit Cheetah Pro is available at Amazfit.com and select retailers worldwide. The Amazfit Helio ring will be released later this spring.
For more information, visit https://www.amazfit.com/en
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240201514405/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom